TERRI SHARO: Open Payments
NPI 1699747204 · NEW CASTLE, PA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$4,203 in 211 payments from 19 companies in 2025. Trend: 2023 $2,643 · 2024 $2,810 · 2025 $4,203
Food & beverage: $4,091Education: $111
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 39 | $1,008 |
| Teva Pharmaceuticals USA, Inc. | 38 | $620 |
| Alkermes, Inc. | 20 | $464 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 16 | $344 |
| Vanda Pharmaceuticals Inc. | 16 | $338 |
| Otsuka America Pharmaceutical, Inc. | 17 | $255 |
| Neurocrine BioSciences, Inc. | 11 | $220 |
| Axsome Therapeutics, Inc. | 12 | $204 |
| Janssen Pharmaceuticals, Inc | 6 | $124 |
| Corium, LLC | 7 | $114 |
Products named: VRAYLAR, CAPLYTA, AUSTEDO XR, FANAPT, REXULTI, LYBALVI, INGREZZA, ARISTADA.
Industry payments across PA — which companies pay providers there.
